New UK Model Agreements To Streamline Clinical Research

Efforts are on to reduce the time it takes to set up commercial studies in UK hospitals.

3D illustration of 3 flows of spheres converging in a single row over black background
Use of templates promotes consistency and can help reduce confusion and delays • Source: Alamy

The UK has developed three new “model agreement” templates to help reduce the time, cost and resources for all parties involved with setting up commercially-sponsored studies in National Health Service (NHS)/Health and Social Care (HSC) hospitals.

The new templates support the government’s ongoing plans to help drive the recovery of non-COVID-19 clinical research through a range of steps

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

More from Europe

EU Wants Industry To Define ‘Trade Secrets’ Under Health Data Sharing Regulation

 

The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.

Safety Review Prompts EMA to Suspend Ixchiq Chikungunya Vaccine For Seniors

 

The European Medicines Agency is investigating whether Valneva’s Ixchiq is safe to use in the elderly, following reports of 17 serious adverse events, including two cases resulting in death, in people aged 62 to 89 years who received the vaccine. This follows actions by US and French authorities last month regarding Ixchiq’s use in people over 65.

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.